The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
The study included four independent genetic substudies targeting obesity caused by heterozygous variants in the POMC/PCSK1, LEPR, SRC1 (NCOA1), and SH2B1 genes
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Subscribe To Our Newsletter & Stay Updated
